Brokers Set Expectations for Curis FY2025 Earnings

Curis, Inc. (NASDAQ:CRIS) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Curis in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the biotechnology company will post earnings of ($2.34) per share for the year. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Curis in a report on Tuesday, December 10th.

Curis Price Performance

CRIS opened at $3.42 on Thursday. The firm has a market capitalization of $28.97 million, a PE ratio of -0.44 and a beta of 3.42. The business’s 50-day moving average is $3.61 and its two-hundred day moving average is $4.71. Curis has a 1 year low of $2.86 and a 1 year high of $17.49.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Curis stock. Point72 Asset Management L.P. lifted its holdings in shares of Curis, Inc. (NASDAQ:CRIS) by 795.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 108,356 shares of the biotechnology company’s stock after acquiring an additional 96,256 shares during the period. Point72 Asset Management L.P. owned approximately 1.84% of Curis worth $748,000 at the end of the most recent quarter. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.